Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Endometrial Cancer: early-phase trial registry
108 of 188 indexed Endometrial Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #59 of 28,707 conditions by registered trial count.
188 US clinical trials · 108 currently recruiting · #59 of 28,707 conditions by registered trial count
Endometrial Cancer: 188 US clinical trials tracked, 108 recruiting.
Endometrial Cancer is the subject of 188 registered US clinical trials on ClinicalTrials.gov, 108 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 118 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 17 of these trials.
Enrollment posture brief
Registry condition endometrial-cancer
OPEN 108 | RECR 57% | LATE 15 | EARLY 118 | RANK #59 | SPON 17
Volume-matched condition peers
Nearest open-share peer: Mesothelioma (57% recruiting · 47 trials)
Endometrial Cancer lists 108 open slots (57% of 188 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Endometrial Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Endometrial Cancer is recruiting above its size-band peers.
108 of 188 indexed trials (57.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Endometrial Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 17 of 188 trials (9%). 116 distinct sponsors appear on at least one study for this condition label.
-
Typical Endometrial Cancer enrolment sits around 108 participants.
Median target enrolment is 108 among the 182 trials that report a genuine target (sentinel values excluded). 85 of those (46.7%) plan for fewer than 100 participants.
-
Endometrial Cancer research is mostly interventional.
167 interventional and 21 observational studies make up this index (88.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
188 total, page 1 of 4
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Avera McKennan Hospital & University Health Center
NCT05142033
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Adela
NCT05366881
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Northwestern University
NCT00005095
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Mayo Clinic
NCT05051722
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
Elephas
NCT07327489
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
Memorial Sloan Kettering Cancer Center
NCT04291612
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
University of Alabama at Birmingham
NCT03538665
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Merck Sharp & Dohme
NCT06952504
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
Weill Medical College of Cornell University
NCT06096688
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
University of California, San Francisco
NCT05056077
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
NCT03564340
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Genmab
NCT05579366
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT06172478
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05208762
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Daiichi Sankyo
NCT07022483
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca
NCT07044336
MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer
Rachel Miller
NCT06677112
Comprehensive Outcomes for After Cancer Health
Pack Health
NCT05349227
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Regeneron Pharmaceuticals
NCT04590326
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
AstraZeneca
NCT06989112
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Genmab
NCT07166094
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
AstraZeneca
NCT05797168
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
BioNTech SE
NCT06340568
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune
NCT05983432
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
AstraZeneca
NCT05123482
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
NCT05489211
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma
NCT04657068
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics
NCT05867251
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Canadian Cancer Trials Group
NCT05640999
Use of an Intrauterine Manipulator and Its Correlation with Positive Peritoneal Cytology in Early Stage Endometrial Cancers
WellSpan Health
NCT04570553
A Study of XMT-1660 in Participants With Solid Tumors
Mersana Therapeutics
NCT05377996
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals
NCT04585750
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor
NCT06276491
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune
NCT06293898
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
Anthony Costales, MD
NCT04586959
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Karyopharm Therapeutics
NCT05611931
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
NCT04104776
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Corcept Therapeutics
NCT06906341
Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer
M.D. Anderson Cancer Center
NCT07382583
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Kartos Therapeutics
NCT05797831
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Whitehawk Therapeutics
NCT07470853
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeiGene
NCT06257264
Vaginal Cuff Brachytherapy Fractionation Study
Kara Romano, MD
NCT03785288
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
NCT06242470
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
Totus Medicines
NCT05683418
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Whitehawk Therapeutics
NCT07444814
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
NCT05787587
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics
NCT07029399
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences
NCT07109726
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma
NCT07227168
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 74 |
| Phase 2 | 44 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Endometrial Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Endometrial Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Endometrial Cancer page
188 registered trials, 108 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 108 Endometrial Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Endometrial Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Endometrial Cancer condition card totals 188 registered trials; most-linked intervention Paclitaxel; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.